DrHarvard immunotherapeutic vaccine is a personalized medicine that uses patient’s own cells (autologous immune cells). It helps patient’s immune system to find out and eliminate cancer cells.
DrHarvard is composed of three parts: Antigen presenting cells (APCs), tumor-associated antigen genes, and adjuvant.
It uses autologous lymphocytes (patient’s B cells & monocytes) as APCs. APCs process foreign antigens and/or impaired cells into peptide fragments and present them to immune cells.
APCs of DrHarvard have tumor-specific antigen genes. They present tumor antigens to immune cells and activate them to eliminate specific tumor cells.
α-galactosylceramide is an adjuvant which potentiate the anti-tumor activities of DrHarvard.
Tumor cells overexpress specific tumor antigens on their surface and by changing the inserted tumor antigen genes, DrHarvard can be used for various cancers.
DrHarvard is a platform technology that can be applied to every cancer with identified tumor antigen.